|
Match
|
Document |
Document Title |
|
|
US20140328819 |
COAGULATION FACTOR VII COMPOSITIONS AND METHODS OF MAKING AND USING SAME
The present invention relates to compositions comprising factor VII coagulation factors linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and... |
|
|
US20170128550 |
Stabilised Solid Compositions of Factor VII Polypeptides
The invention relates to chemically as well as physically stable compositions comprising Factor VII or a Factor VII-related polypeptide such that these compositions can be stored, handled and used... |
|
|
US20170080061 |
MODIFIED COAGULATION FACTOR VIIa WITH EXTENDED HALF-LIFE
The present invention relates to the fields of Factor VII (FVII) and Factor VIIa (FVIIa) albumin linked polypeptides. More specifically, the invention relates to cDNA sequences coding for human... |
|
|
US20170042979 |
TARGETING OF GLYCOPROTEIN THERAPEUTICS
Methods of making ligand-decorated polymer conjugates of therapeutic glycoproteins are described. Improved targeting of glycoproteins to specific tissues is achieved by masking the natural... |
|
|
US20170035896 |
POLYMER FACTOR IX MOIETY CONJUGATES
Conjugates of a Factor IX moiety and one or more water-soluble polymers are provided. Typically, the water-soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided (among... |
|
|
US20160074515 |
VISCOSITY-REDUCING EXCIPIENT COMPOUNDS FOR PROTEIN FORMULATIONS
The invention encompasses formulations and methods for the production thereof that permit the delivery of concentrated protein solutions. The inventive methods can yield a lower viscosity liquid... |
|
|
US20150343080 |
GLYCOPEGYLATION METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE METHODS
The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a... |
|
|
US20150291562 |
IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE
The description relates to imide-based compounds, including bifunctional compounds comprising the same, which find utility as modulators of targeted ubiquitination, especially inhibitors of a... |
|
|
US20150165059 |
SOLUBLE GLYCOSAMINOGLYCANASES AND METHODS OF PREPARING AND USING SOLUBLE GLYCOSAMINOGLYCANASES
The invention relates to the discovery of novel soluble neutral active Hyaluronidase Glycoproteins (sHASEGPs), methods of manufacture, and their use to facilitate administration of other molecules... |
|
|
US20140294762 |
GLYCOPEGYLATION METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE METHODS
The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a... |
|
|
US20130336948 |
COSMETIC
A composition is provided that includes a fish spawn protein isolate. A natural product extract is also present that includes unsaturated fatty acids and sterols. An emulsifier is provided to form... |
|
|
US20120321606 |
CRYSTAL STRUCTURES AND METHODS USING SAME
The present invention relates generally to the fields of molecular biology and growth factor regulation. More specifically, the invention concerns modulators of FGFR3 function, and the... |
|
|
US20120064075 |
CHIMERIC FACTOR VII MOLECULES WITH ENHANCED HALF LIFE AND METHODS OF USE
The present invention relates to novel proteins and methods of using chimeric Factor VIIa polypeptides. |
|
|
US20110091437 |
FUSION PROTEINS
A single chain, polypeptide fusion protein, comprising: a non-cytotoxic protease, or a fragment thereof, which protease or protease fragment is capable of cleaving a protein of the exocytic fusion... |
|
|
US20110064714 |
FACTOR VIIA-POLYSIALIC ACID CONJUGATE HAVING PROLONGED IN VIVO HALF-LIFE
The present invention relates to a proteinaceous construct comprising plasmatic or recombinant factor VIIa (FVIIa) or biologically active derivatives thereof, which are bound to a carbohydrate... |
|
|
US20100158803 |
Production and Use of Novel Peptide-Based Agents for Use with Bi-Specific Antibodies
The present invention relates to a bi-specific antibody or antibody fragment having at least one arm that is reactive against a targeted tissue and at least one other arm that is reactive against... |
|
|
US20070148151 |
PROCESSES FOR THE MANUFACTURE AND USE OF PANCREATIN
A process for the manufacture and use of pancreatin in which the concentration of one or more biological contaminants is reduced, such as viruses and/or bacteria, through heating the pancreatin at... |
|
|
US20050147687 |
Methods for fabrication, uses and compositions of small spherical particles of AAT prepared by controlled phase separation
The present invention is related to a method for preparing small spherical particles of an active agent by providing a solution in a single liquid phase. The single liquid phase comprises an... |
|
|
US20170014520 |
OLIGOSACCHARIDES COMPRISING AN AMINOOXY GROUP AND CONJUGATES THEREOF
The invention provides methods for the synthesis of oligosaccharides comprising an aminooxy group. The invention further provides oligosaccharides comprising an aminooxy group, methods for... |
|
|
US20170007679 |
CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING HIV INFECTION AND AIDS
CRISPR/CAS-related compositions and methods for treatment of a subject at risk for or having a HIV infection or AIDS are disclosed. |
|
|
US20170000859 |
NON-NATURAL RIBONUCLEASE CONJUGATES AS CYTOTOXIC AGENTS
The present invention is directed toward the delivery of a toxic protein to pathogenic cells, particularly cancer cells. In preferred embodiments, the toxic protein is a ribonuclease that has been... |
|
|
US20150265719 |
SYSTEMS AND METHODS OF DELIVERY OF BIOACTIVE AGENTS USING BACTERIAL TOXIN-DERIVED TRANSPORT SEQUENCES
The field of the present invention relates, in part, to a strategy for novel pharmaceutical applications. More specifically, the present invention relates to a non-toxic mutant form of the Vibrio... |
|
|
US20150265718 |
SYSTEMS AND METHODS OF DELIVERY OF BIOACTIVE AGENTS USING BACTERIAL TOXIN-DERIVED TRANSPORT SEQUENCES
The field of the present invention relates, in part, to a strategy for novel pharmaceutical applications. More specifically, the present invention relates to a non-toxic mutant form of the Vibrio... |
|
|
US20150182588 |
SYNTHETIC MEMBRANE-RECEIVER COMPLEXES
Compositions comprising synthetic membrane-receiver complexes, methods of generating synthetic membrane-receiver complexes, and methods of treating or preventing diseases, disorders or conditions... |
|
|
US20150165054 |
METHODS FOR CORRECTING CASPASE-9 POINT MUTATIONS
Some aspects of this disclosure provide strategies, systems, reagents, methods, and kits that are useful for the targeted editing of nucleic acids, including editing a nucleic acid encoding a... |
|
|
US20140186323 |
FACTOR VIIA-POLYSIALIC ACID CONJUGATES HAVING PROLONGED IN VIVO HALF-LIFE
The present invention relates to a proteinaceous construct comprising plasmatic or recombinant factor VIIa (FVIIa) or biologically active derivatives thereof, which are bound to a carbohydrate... |
|
|
US20140127181 |
Stabilised Compositions of Factor VII Polypeptides
The invention relates to chemically as well as physically stable kits and compositions comprising polypeptides, in particular Factor VII or Factor VII-related polypeptides, such that these... |
|
|
US20130129726 |
PEPTIDE HAVING CELL MEMBRANE PENETRATING ACTIVITY
Provided are transmembrane complexes that contain a protein transduction domain (PTD) from the N-terminus of IgE-dependent histamine-releasing factor (HRF) and a target substance that is to be... |
|
|
US20110287004 |
MG53 COMPOSITIONS AND METHODS OF USE
Disclosed herein are nucleic acid sequences that encode novel polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies, which immunospecifically-bind... |
|
|
US20050281799 |
Targeting damaged lung tissue using compositions
The present invention relates to methods and compositions for targeting damaged lung tissue. Compositions provided feature a targeting moiety coupled to one or more other moieties, including, for... |
|
|
US20160298136 |
CRISPR-BASED GENOME MODIFICATION AND REGULATION
The present invention provides RNA-guided endonucleases, which are engineered for expression in eukaryotic cells or embryos, and methods of using the RNA-guided endonuclease for targeted genome... |
|
|
US20150174266 |
APROTININ POLYPEPTIDES FOR TRANSPORTING A COMPOUND ACROSS THE BLOOD-BRAIN BARRIER
The invention relates to improvements in the field of drug delivery. More particularly, the invention relates to polypeptides derived from aprotinin and from aprotinin analogs as well as... |
|
|
US20150147276 |
NANOTHERAPEUTICS FOR DRUG TARGETING
The invention provides compositions and methods for targeted controlled drug release. The compositions and methods can be used for treating or imaging vascular stenosis, stenotic lesions, occluded... |
|
|
US20140227185 |
GLUTATHIONE-BASED DRUG DELIVERY SYSTEM
The invention relates to methods of targeted drug delivery of compounds, including, chemical agents, (poly)peptides and nucleic acid based drugs (like DNA vaccines, antisense oligonucleotides,... |
|
|
US20120100121 |
Pegylated L-Asparaginase
Disclosed is a conjugate of a protein having substantial L-asparagine aminohydrolase activity and polyethylene glycol. In particular, the polyethylene glycol has a molecular weight less than or... |
|
|
US20120076779 |
STABILIZATION OF IMMUNOGLOBULINS AND OTHER PROTEINS THROUGH AQUEOUS FORMULATIONS WITH SODIUM CHLORIDE AT WEAK ACIDIC TO NEUTRAL ph
The present invention provides, among other aspects, storage stabile aqueous formulations of labile proteins at a mildly acidic to neutral pH. The present invention also provides methods for... |
|
|
US20110123509 |
FUSION MOLECULES OF RATIONALLY-DESIGNED DNA-BINDING PROTEINS AND EFFECTOR DOMAINS
Targeted transcriptional effectors (transcription activators and transcription repressors) derived from meganucleases are described. Also described are nucleic acids encoding same, and methods of... |
|
|
US20090208474 |
BIOLOGICAL ENTITIES AND THE USE THEREOF
The present invention provides engineered enzymes generated from protein scaffolds combined with Specificity Determining Regions, the production thereof and the use of said engineered enzymes for... |
|
|
US20050281800 |
Targeting sites of damaged lung tissue
The present invention relates to methods and compositions for targeting damaged lung tissue. Compositions provided feature a targeting moiety coupled to one or more other moieties, including, for... |
|
|
US20050042211 |
System and method for high resolution videoconferencing
A system and method for high resolution video conferencing is shown and described. A transmitting station and a receiving station including video cameras or sensors, a plurality of microphones and... |
|
|
US20160199503 |
MODIFIED BLOOD FACTORS COMPRISING A LOW DEGREE OF WATER SOLUBLE POLYMER
The present invention relates, in general, to materials and methods for the preparation of modified blood factors which have low levels of water soluble polymer molecules conjugated to the blood... |
|
|
US20150125437 |
Glycopegylated Factor IX
Conjugates between Factor IX and PEG moieties. are disclosed in the present application. The conjugates are linked via a glycosyl linking group interposed between and covalently attached to the... |
|
|
US20130216513 |
Chimeric Clotting Factors
Chimeric clotting factors which localize the therapeutic to sites of coagulation (e.g., by being targeted to platelets or being activatable at sites of coagulation), have reduced clearance rates,... |
|
|
US20130189239 |
Conjugated Factor VIII Molecules
The present invention relates to B-domain truncated Factor VIII molecules with a modified circulatory half life, said molecule being covalently conjugated with a hydrophilic polymer. The invention... |
|
|
US20130084274 |
Liquid, Aqueous Pharmaceutical Compositions of Factor VII Polypeptides
The present invention is directed to liquid, aqueous pharmaceutical compositions stabilised against chemical and/or physical degradation containing Factor VII polypeptides, and methods for... |
|
|
US20120219506 |
Catenae: Serosal Cancer Stem Cells
The present invention relates to a clonally pure population of serosal cancer stem cells (CSCs) as well as methods of producing and culturing the CSCs and uses thereof. The CSCs form catenae (free... |
|
|
US20110195077 |
METHODS AND COMPOSITIONS USING FGF23 FUSION PPOLYPEPTIDES
The present disclosure is directed to methods, kits and compositions for preventing or treating age-related conditions or metabolic disorders. The fusion polypeptides of the disclosure include... |
|
|
US20100310576 |
COMPOSITIONS AND METHODS COMPRISING ASPARTYL-tRNA SYNTHETASES HAVING NON-CANONICAL BIOLOGICAL ACTIVITIES
Isolated aspartyl-tRNA synthetase polypeptides and polynucleotides having non-canonical biological activities are provided, as well as compositions and methods related thereto. |
|
|
US20100221213 |
Y-SHAPE BRANCHED HYDROPHILIC POLYMER DERIVATIVES, THEIR PREPARATION METHODS, CONJUGATES OF THE DERIVATIVES AND DRUG MOLECULES, AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE CONJUGATES
The present invention relates to Y-shape branched PEG derivatives of formulae (I) to (IV). The present invention also relates to conjugates of these Y-shape derivatives and drug molecules,... |
|
|
US20100215575 |
Systemic Administration of Chlorotoxin Agents for the Diagnosis and Treatment of Tumors
The present invention is directed to methods and compositions for the treatment and diagnosis of neoplastic tumors. The inventive methods generally include systemic (e.g., intravenous)... |